NEW YORK GENOME CENTER INC
Programs
Program 1 [2020]
RESEARCH AND RESEARCH SEQUENCING: NYGC'S RESEARCH SCIENTISTS AND FACULTY CONDUCT RESEARCH INTO THE GENETIC FACTORS THAT CONTRIBUTE TO HUMAN DISEASE, BOTH IN THEIR OWN PROJECTS AND THROUGH COLLABORATIONS. NYGC RESEARCHERS HAVE PROJECTS UNDERWAY IN CANCER, INCLUDING LUNG, LIVER, BREAST AND MELANOMA, A MULTISITE VERY RARE CANCER PROJECT AND A LARGE COLLABORATIVE PROJECT STUDYING CANCER IN UNDERSERVED POPULATIONS IN NYC; NEURODEGENERATIVE DISEASES, INCLUDING ALS AND DEMENTIA AND NEUROPSYCHIATRIC DISEASES, FOCUSING ON AUTISM, AMONG OTHERS. IN 2020, NYGC SEQUENCED OVER 8,300 WHOLE GENOME SAMPLES, COMPLETED 396 PROJECTS, AND COLLABORATED WITH 82 INVESTIGATORS FROM 41 INSTITUTIONS WORLDWIDE. FOR MORE INFORMATION SEE SCHEDULE O.GeographiesNot indicatedDatesJan 1, 2020 – Dec 31, 2020Source990No causes providedNo populations provided–$53MProgram 2 [2020]
CLINICAL SEQUENCING: NYGC IS AUTHORIZED BY THE NEW YORK STATE DEPARTMENT OF HEALTH TO OFFER THE FOLLOWING APPROVED CLINICAL TESTS THROUGH ITS CLEP/CLIA CERTIFIED CLINICAL LABORATORY: CONSTITUTIONAL WHOLE GENOME SEQUENCING FOR UNDIAGNOSED DISEASE, CONSTITUTIONAL WHOLE GENOME SEQUENCING FOR PREDISPOSITIONAL GENETIC SCREENING, ONCOLOGY WHOLE GENOME AND TRANSCRIPTOME SEQUENCING, CONSTITUTIONAL WHOLE EXOME SEQUENCING, TARGETED VARIANT TESTING USING SANGER SEQUENCING, ONCOLOGY WHOLE EXOME AND TRANSCRIPTOME SEQUENCING, AND THE SMASH GENOMIC ASSAY.GeographiesNot indicatedDatesJan 1, 2020 – Dec 31, 2020Source990No causes providedNo populations provided–$4.5MGenome Sequencing Program
GENOME SEQUENCING: THE NEW YORK GENOME CENTER (NYGC) HAS ONE OF NEW YORK'S LARGEST AND MOST ADVANCED WHOLE GENOME SEQUENCING PROGRAMS, HAVING SEQUENCED OVER 106,885 WHOLE GENOME SAMPLES TO DATE. NYGC'S TWO STATE-OF-THE-ART ILLUMINA NOVASEQ X SYSTEMS SEQUENCERS ARE EACH CAPABLE OF SEQUENCING 20,000 HUMAN GENOMES ANNUALLY. THIS STATE-OF-THE-ART SEQUENCING TECHNOLOGY ENABLES NYGC TO CONDUCT LARGE-SCALE GENOMICS PROJECTS WITH GREAT SPEED AND SAMPLE VOLUMES, AND TO EXPLORE THE GENOME IN MORE DEPTH WITH GREATER EFFICIENCY. IN ADDITION, NYGC OPERATES AN OXFORD NANOPORE PROMETHION SEQUENCER FOR LONG READ SEQUENCING, AND A HIGH-THROUGHPUT SEQUENCER FROM ULTIMA GENOMICS (THE UG100). SEE SCHEDULE O.GeographiesNot indicatedDatesJan 1, 2024 – Dec 31, 2024Source990No causes providedNo populations provided–$60.5M
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)